Illumina Names Francis deSouza as President
News Nov 12, 2013
He will also become part of Illumina's executive management team, which is responsible for directing all aspects of company strategy, planning and operations. Mr. deSouza has nearly two decades of technology experience and has successfully brought products to market in startups and large organizations.
"Francis' broad technology background, his experience in providing complex technology solutions, and his roles in scaling and leading both entrepreneurial startups and large enterprises make him ideal for the role," said Jay Flatley. "We are very excited to have Francis join our team as he brings a unique combination of global expertise, business acumen and technology depth."
Mr. deSouza currently serves as President of Products & Services at Symantec Corporation, where he is responsible for driving the vision for Symantec's market-leading portfolio, and is part of the executive team setting the company's strategic direction. Prior to his current role, he served in a variety of executive roles at Symantec, joining the company through the acquisition of IMlogic in February of 2006, where he was co-founder and CEO. Before his years at IMlogic and Symantec, Mr. deSouza was co-founder and CEO of Flash Communications, a provider of corporate instant messaging that was acquired by Microsoft in 1998. Following that acquisition, he joined Microsoft and led the team responsible for the development of the company's enterprise real-time collaboration offerings. He currently serves as Chairman of the Board for MedHelp, the world's largest online health community. Mr. deSouza holds a number of patents in computer security, and graduated from the Massachusetts Institute of Technology with MS and BS degrees in Electrical Engineering and Computer Science. Mr. deSouza will join the Illumina team in December.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018